EMA Grants First Marketing Authorization for Albireo's Rare Liver Disease Treatment, Bylvay (odevixibat)
First PFIC-targeted therapy Bylvay approved European Medicines Agency (EMA) has officially approved Albireo Pharma's bile acid transporter (IBAT, Ileal Bile Acid Transporter) inhibitor 'Bylvay (generic name odevixibat)' as a treatment for progressive familial intrahepatic cholestasis (PFIC, Progressive Familial Intrahepatic Cholestasis) in children aged 6 months and older. The item has been permitted. The approval of this treatment marks a fundamental shift in the paradigm for pediatric liver disease management, as PFIC patients previously had no approved pharmacological options other than liver transplantation or bile diversion surgery. Following a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP), final approval was swiftly granted, opening immediate commercialization pathways across all 27 member states of the European Union (EU). This approval is a significant regulatory milestone that demonstrates Albireo's leadership in the field of rare pediatric liver diseases and maximizes its commercial value.
PEDFIC Phase 3 Trials Demonstrate Improvement in Bile Acids and Pruritus
This approval was based on data from the largest-ever Phase 3 study for PFIC, PEDFIC 1, and its extension trial, PEDFIC 2. In the PEDFIC 1 trial, the Bylvay group demonstrated a response rate of 33.3% in reducing serum bile acid (sBA) by more than 70% or to below 70 μmol/L, showing statistically significant superiority over the placebo group (0%) (p=0.003). Furthermore, significant symptom relief was confirmed in the secondary endpoint of pediatric pruritus, an indicator that severely disrupts patient sleep and quality of life, thereby fully meeting the primary endpoint. By securing excellent tolerability, with most adverse events limited to mild diarrhea and no serious adverse reactions, we have addressed safety concerns regarding long-term use in pediatric patients.
IBAT Inhibitor Mechanism and Market Competition with Mirum
Odevixibat utilizes an innovative mechanism that blocks the reabsorption of bile acids in the distal small intestine during the enterohepatic circulation process, thereby excreting toxic bile acids that accumulate in the liver. Unlike its competitor in the same class, Mirum Pharmaceuticals' (ticker: MIRM) Livmarli (maralixibat), which initially focused on Alagille syndrome (ALGS), Bylvay has secured a first-mover advantage by being registered as the first drug for the PFIC indication in Europe. The development of a once-daily oral capsule formulation, designed so that patients can open the capsule and sprinkle its contents on food, is cited as a differentiating factor that significantly improves medication adherence in pediatric patients.
$1 Billion Blockbuster Potential Drives Ipsen's $952 Million M&A
The 10-year market exclusivity granted by the European Orphan Drug designation acted as a catalyst to rapidly increase Albireo's enterprise value. With the indication expansion to Alagille syndrome (ALGS) and biliary atresia becoming apparent following PFIC, global peak sales forecasts surpassed $750 million. Ultimately, this commercial potential served as the decisive trigger for the 2023 big deal in which the French pharmaceutical company Ipsen acquired Albireo at $42 per share, with an upfront payment of $952 million and an additional $120 million Contingent Value Right (CVR), totaling $1.07 billion.
Vibie secured its first marketing authorization from European regulators by demonstrating Phase 3 PEDFIC 1 data (bile acid response rate 33.3% vs. 0%, p=0.003) in the global PFIC market, which previously lacked approved therapies and has an incidence of 1 per 50,000 to 100,000 newborns. This means that they have secured a first-mover advantage in the European PFIC market, ahead of competitor MIRM Pharma's Revlimid, and established strong barriers to entry for 10 years through EU orphan drug designation. In the short term, revenue generation is expected through price negotiations in 27 European countries and early launch. In the medium to long term, a foundation has been established to evolve into a blockbuster-level peak revenue pipeline exceeding $750 million annually by expanding indications for Alagille syndrome (ALGS) and biliary atresia. This approval is evaluated as a key commercialization milestone that led to France's Ipsen (IPN) acquiring Albireo (ALBO) for a total of $1.07 billion, including an upfront payment of $952 million ($42 per share) and CVR.
Source: EMA (ema)